Journal
ANTIVIRAL RESEARCH
Volume 84, Issue 2, Pages 150-158Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2009.08.004
Keywords
Coxsackie virus B3; Viral myocarditis; Phyllaemblicin B; Antiviral effect; Apoptosis
Categories
Funding
- Funds of National Science Foundation of China [U0632010]
- State Key Laboratory of Phytochemistry and Plant Resources in West China
- Kunming Institute of Botany, Chinese Academy of Sciences [P2008-KF07, P2008-ZZ08]
- Ministry of Education (MOE)
Ask authors/readers for more resources
Coxsackie virus B3 (CVB3) is believed to be a major contributor to viral myocarditis since virus-associated apoptosis plays a role in the pathogenesis of experimental myocarditis. in this study, we investigated the in vitro and in vivo antiviral activities of Phyllaemblicin B, the main ellagitannin compound isolated from Phyllanthus emblica, a Chinese herb medicine, against CVB3. Herein we report that Phyllaemblicin B inhibited CVB3-mediated cytopathic effects on HeLa cells with an IC50 value of 7.75 +/- 0.15 mu g/mL In an in vivo assay, treatment with 12 mg kg(-1) d(-1) Phyllaemblicin B reduced cardiac CVB3 titers, decreased the activities of LDH and CK in murine serum, and alleviated pathological damages of cardiac muscle in myocarditic mice. Moreover, Phyllaemblicin B clearly inhibited CVB3-associated apoptosis effects both in vitro and in vivo. These results show that Phyllaemblicin B exerts significant antiviral activities against Phyllaemblicin B may represent a potential therapeutic agent for viral myocarditis. Therefore CVB3. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available